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Loss of caspase-8 expression and resistance to cytotoxic agents occurs frequently in late stage neuroblastoma (NB). Interferon-γ (IFN-γ)
induces caspase-8 in NB cells, sensitizing them to death receptor mediated apoptosis. This study characterizes the kinetics of this phenomenon and
examines the effects of IFN-γ on global gene expression to determine whether IFN-γ responses are achievable at physiologically relevant doses
and to define the biological effects of this cytokine. Here we examine the IFN-γ responses of 16 NB cell lines. A single <5-min exposure to IFN-γ
(0.5 ng/ml) induced caspase-8 expression in all non-expressing cell lines and in 3/6 cell lines which already expressed high caspase-8. This
increase in caspase-8 proteins was observed within 16 h and persisted for up to 9 days. Furthermore, IFN-γ pretreatment of NB cells increased
doxorubicin-induced apoptosis nearly 3-fold. Microarray analysis was used to identify additional genes involved in proliferation, signaling and
apoptosis whose expression was modulated via IFN-γ. Altered expression of these genes should further enhance the responsiveness of NB cells to
chemotherapeutics. Thus, the use of IFN-γ to sensitize NB cells to cytotoxic agents represents an attractive therapeutic strategy and warrants
further investigation.
© 2006 Elsevier B.V. All rights reserved.Keywords: Interferon-γ; MYCN; Neuroblastoma; Caspase-8; Apoptosis; Microarray1. Introduction
Apoptosis in multicellular organisms is a tightly regulated
process required for normal growth, development, and cellular
specialization. Defective expression of proteins and aberrant
function of constituents in the apoptotic cascade have been
implicated in oncogenesis, tumor progression, and treatment
resistance [1–4]. Two distinct arms of the apoptotic pathway
predominate in chemotherapeutic drug-induced cell death: the
death receptor (or extrinsic) pathway and the mitochondrial (or
intrinsic) pathway. Stimulation of death receptors of the tumor
necrosis factor (TNF) family, CD95/APO-1/Fas, DR4, and⁎ Corresponding author. Tel.: +1 901 495 3501; fax: +1 901 495 2381.
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doi:10.1016/j.bbamcr.2006.06.014DR5, convert quiescent procaspase-8 and procaspase-10
molecules to their active forms, caspase-8 and caspase-10.
These initiator caspases then activate other downstream
proapoptotic caspases and factors resulting in cell death. One
downstream target of caspase-8 is Bid, a proapoptotic bcl-2
family member. Upon activation, Bid facilitates cytochrome-c
release from the mitochondria, thereby activating the mitochon-
drial arm of the intrinsic pathway. A distinct set of
chemotherapeutic drugs and other cellular stresses initiate
apoptosis at the mitochondrial level, which results in the release
of cytochrome-C, Apaf-1, and caspase-9 into the cytosol [1–4].
These mitochondrial proteins associate with calcium ions and
form the apoptosome, which ultimately activates caspase-3.
Caspase-3 activates multiple caspases (downstream and up-
stream) including caspase-8. When activated in this manner,
caspase-8 functions in an amplification loop with caspase-3 to
enhance and accelerate the apoptotic response [5–7].
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myc amplification, has been observed in advanced stage or high
risk neuroblastoma (NB), large cell medulloblastoma, alveolar
rhabdomyosarcoma, and small cell lung carcinoma, all of which
are tumors of neural or neuroectodermal origin [2,8–13].
Decreased caspase-8 expression has been correlated with
methylation of both CASP-8 alleles in a region located at the
exon3/intron3 boundary and not with methylation of promoter
sequences or with gene mutations or deletions such as those
commonly seen in tumor suppressor genes [13]. Despite this
correlation, a cause effect relationshipbetween themethylationof
these sites and caspase-8 expression has not been established to
date. However, NB cells with absent or diminished caspase-8
expression demonstrated marked resistance to death-inducing
stimuli such as TNFá, TRAIL, cycloheximide, and some
chemotherapeutic agents (e.g., doxorubicin), all of which
activate the extrinsic arm of the apoptotic pathway in NB cells
in vitro [13–15].
Induction of endogenous caspase-8 expression with DNA
methyltransferase inhibitors (DNMTi), such as 5-azacytidine, or
following transduction of tumor cells with caspase-8-expressing
retroviruses reconstituted a functional extrinsic apoptotic path-
way, resensitizing the tumor cells to cytotoxic agents and
significantly enhancing apoptosis in vitro [13–15]. Although
theoretically possible, practical application of DNMTi, caspase-
8-expressing retroviruses, or both in vivo is only now being
examined [16]. Phase 1 clinical trials are currently in progress to
determine the feasibility, side effects, toxicity and usefulness of
DNMTi in neuroblastoma patients. Importantly, recent studies
indicate that exposure to DNMTi may be associated with tumor
induction in mice [17,18], though extrapolation of these data to
humans remains controversial [19].
Recently, interferon-γ (IFN-γ) has been shown to induce
caspase-8 expression in NB cell lines, irrespective of the
methylation status of the CASP8 gene, rendering the cells
sensitive to cytotoxic stimuli [20–25]. However, the previous
studies have not determined the threshold dose required for
caspase-8 expression or examined the kinetics of γ-IFN
mediated caspase-8 induction in detail. Therefore it is unclear
whether this response could reasonably be achieved in vivo.
Furthermore, although it has been established that IFN-γ
influences the expression of numerous genes [26–28] many of
which inhibition of cell growth and/or stimulation of cell
differentiation [26–28], the effects of IFN-γ on gene expression
in NB have not been characterized in detail. Here we evaluate
the concentration dependence of IFN-γ associated apoptotic
sensitization and determine the time course and duration of this
process in detail. We confirm that treatment with IFN-γ and
doxorubicin together amplifies the apoptotic responses of NB
cells to these agents, and establish that sequential administration
of IFN-γ followed by doxorubicin is necessary to achieve
maximal cell death. Finally, we describe the overall effect of
IFN-γ on gene expression in neuroblastoma using microarray
analysis to identify changes in mRNA expression, thereby
allowing us to determine how this cytokine influences NB cell
growth and chemoresponsiveness. The preclinical studies
presented here suggest that IFN-γ could be used as a therapeuticagent in NB patients and that further studies using xenograph
models are warranted.
2. Materials and methods
2.1. Cell Lines and culture methods
The human NB cell lines used in these studies have been described in detail
elsewhere [13,29]. Cells were maintained in culture in RPMI 1640 medium
supplemented with 10% FBS, 2 mM L-glutamine, and 0.1% gentamicin
Invitrogen (Carlsbad, CA) in a humidified atmosphere of 5% CO2 at 37 °C.
2.2. Reagents
Doxorubicin, IFN-γ and 5-Aza-2′deoxycytidine were purchased from
Sigma (St. Louis, MO). z-IETD-fmk, a caspase inhibitor with high specificity
for caspase-8, was purchased from Enzyme System Products, Valeant
Pharmaceuticals International (Costa Mesa, CA). All reagents were prepared
and stored according to the manufacturer's instructions.
2.3. Treatment of cells
For caspase-8 expression studies, cells were plated at a density of 3.5×105
cells/60 mm dish, allowed to adhere to the culture dish, and then treated with
IFN-γ (0.5–100 ng/ml) for different periods of time (5 min to 24 h) as indicated
in the figures. In experiments lasting longer than 48 h the culture media was
replaced with fresh media every 48 h. In studies using 5-aza-2′deoxycytidine
and IFN-γ, the demethylating agent (1 or 5 μM) was administered every 24 h for
2 days. The cells were then treated with IFN-γ (100 ng/ml) for 120 min, washed
with PBS, and incubated in fresh media for an additional 16 h before harvest. For
studies involving both doxorubicin and IFN-γ, IFN-γ treatment preceded
doxorubicin administration by 24 h. Doxorubicin (0.1 μg/ml) exposure was
maintained for an additional 48 h before the cells were harvested for TUNEL
analysis.
For the functional studies, cells were plated as previously described [13]. In
the IFN-γ treatment group, NB cells were treated with IFN-γ (100 ng/ml) for
120 min. IFN-γ was then removed, and the cells were allowed to recover for 16
h before harvest for further analysis. In the studies with both doxorubicin and
IFN-γ treatment, IFN-γ (100 ng/ml) was administered on day 1 as described
above and doxorubicin (0.1 μg/ml) was applied on days 2 and 3. In experiments
involving z-IETD-fmk (50 μM), the inhibitor was present in the culture medium
for the duration of the experiment. Culture dishes from all treatment groups were
harvested on day 4 and analyzed for apoptosis by TUNEL as described below.
2.4. Immunoblot analysis for caspase-8 expression
Immunoblots containing 25 to 50 μg of total cellular protein lysate were
prepared as described previously [29]. Immunoblots were sequentially
incubated with mouse anti-caspase-8 C15 monoclonal antibody (1/50) [30]
or an anti-actin control antibody Santa Cruz Biotechnology Inc (Santa Cruz,
CA) (1:1000) and a 1:4000 dilution of horseradish peroxidase-conjugated IgG
goat anti-mouse secondary antibody Kierkegaard and Perry Laboratories
(Gaithersburg, MD). ECL Western blotting detection reagents from GE
Healthcare (Piscataway, NJ) were used to detect bound antibodies on the
immunoblots.
2.5. Bisulfite Treatment and Methylation-Specific Polymerase Chain
Reaction
Tumor cell genomic DNA (gDNA) was isolated with DNAzole (Molecular
Research Center, Inc., Cincinnati, OH) according to the manufacturer's
specifications. The final product was resuspended in 10 mM Tris–HCl (pH 7.5)
and 0.1 mM EDTA and then quantified via standard spectrophotometric
analysis.
The gDNA (1 μg) was bisulfite-modified by using the CpGenome DNA
Modification kit (Intergen, Purchase, NY) according to the manufacturer's
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polymerase chain reaction (MS-PCR) studies using the caspase-8 methylation
primer sets previously described [13]. Reaction conditions included 4 mM
MgCl2, 20 nM each of the 5′ and 3′ primers, 10 μM dNTPs (2.5 μM of each
nucleotide), and 0.5 μg of bisulfite-modified gDNA. All reactions were initially
incubated at 95 °C for 10 min, and 0.5 μl Taq polymerase was added after 5 min.
The MS-PCR using the unmethylated primer set included 32 cycles of 95 °C for
30 s, 61 °C for 30 s, and 72 °C for 45 s followed by a single cycle at 72 °C for
4 min; this reaction yielded a 322-bp fragment. Analysis using the methylated
primer set included 35 cycles at 95 °C for 30 s, 63 °C for 30 s, and 72 °C for 45 s
followed by a single cycle at 72 °C for 4 min; this reaction yielded a 321-bp
fragment.
2.6. Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) analysis was performed as
described previously using fluorochrome-labeled human TNFR2 and centro-
meric chromosome 1p probes as controls, a P1 phage probe for human CASP8,
and a cosmid probe containing human MYCN to determine whether the
expression of MYCN was amplified in NB cells [13].
2.7. Analysis of apoptosis by TUNEL
In situ labeling of apoptosis-induced DNA strand breaks was carried out
using an In Situ Cell Death Detection kit (Roche Diagnostics, Indianapolis, IN)
according to the manufacturer's instructions. Briefly, 3–4 slides containing a
minimum of 700 cells were analyzed from 2 independent experiments. Cells
were grown to 75% confluence on 60-mm culture plates. Cytospin preparations
were made and the cells were fixed with paraformaldehyde and permeabilized
with sodium citrate. TUNEL (terminal deoxinucleotidyltransferase-mediated
dUTP-biotin nick-end-labeling) reagent was applied followed by Vectashield
(4,6-diaminido-2 phenylindole) Vector Laboratories (Burlington, CA) applica-
tion. Samples were analyzed for apoptotic events by visualization using
indirect immunofluorescence microscopy. Intact cells displaying brightly
stained nuclei with concurrent blebbing of the cell membrane were counted
as apoptotic cells. The apoptotic index was determined by assessing the
fraction of apoptotic cells in at least 8 to 10 high-powered fields on duplicate
slide preparations; 700 to 800 cells were counted for each sample. Standard
error of the mean was calculated for the data from three independent
experiments.
2.8. RNase protection assay
RNA was isolated from the NB cell lines using TriReagent Invitrogen
(Carlsbad, CA) per the manufacturer's instructions. Fifteen micrograms of total
RNAwas used for the RNAse protection analyses. These assays were performed
using the hApoI and hApoIII RNase protection kits according to the
manufacturer's directions BD Bioscience (San Diego, CA).
2.9. Microarray studies
Microarray analyses were conducted on the NB10, NB16, NB19, and
NB1643 cells, all of which expressed wild-type p53. NB16 and NB1643
expressed caspase-8 and did not have amplified MYCN; NB10 and NB19 did
not express caspase-8 and had amplified MYCN. Each cell line was treated
with IFN-γ (100 μg/ml) for 2 h and then allowed to recover for 24 h prior to
harvesting. RNA was obtained from control and IFN-γ-treated NB cells from
three independent experiments using TRIzol reagent Invitrogen (Carlsbad, CA)
as described by the manufacturer. The total RNAwas further purified using the
RNeasy Mini Kit Qiagen (Valencia, CA) to remove any residual genomic
DNA.
For microarray analysis, five micrograms of total RNA from each sample
was amplified using the MessageAmp RNA Amplification kit Ambion (Austin,
TX). The amplified mRNAwas then used to generate cDNA. Cye dye labeling
was performed using an indirect, random hexamer-labeling method. Microarray
analyses were performed according to MIAME, (minimum information about
microarray experiments) standards. Human cDNA microarrays containingapproximately 10,000 spots printed on each poly-lysine-coated slide were
fabricated by the staff of the Functional Genomics Facility in the Hartwell
Center for Bioinformatics and Biotechnology at St Jude Children's Research
Hospital. All microarray experiments were performed in triplicate using
separate biological samples. After hybridization, raw TIFF images from the
scanner were uploaded to GenePix Pro version 4.1 (Axon Inc., Union City, CA)
for analysis. Spot grids (.gal files) were manually fitted to the microarray
images. The resulting GenePix files (.gpr files) were exported into Spotfire
DecisionSite for Functional Genomics version 8.0 Spotfire Inc (Somerville,
MA), and results were filtered to remove unreliable data on the basis of the
signal-to-noise ratio [31]. The R statistical language-based Bioconductor version
1.9 (www.bioconductor.org) was used to perform further analyses, to normalize
the dataset in an intensity-dependent manner [32], and to perform statistical
analyses (i.e., t-test and ANOVA). Changes in the expression of genes were
identified as statistically significant using volcano plots in Spotfire that took into
account both the P-value and the fold change in expression. Changes in
expression were counted as significant only if expression levels in all three
experiments varied by at least 2-fold and the data had statistical P-values <0.05.
Using the Ingenuity Pathways Analysis Solution and Ingenuity Pathways
Knowledge Base Ingenuity Systems (Mountain View, CA) software programs,
several networks of gene interactions with significant network scores were
identified. The network score (negative log of P-value) indicates the probability
that a pathway can be formed through the chance assembly of its members. The
networks were then joined on the basis of overlapping genes, and the most
abundant functional categories were determined.
2.10. Real-time PCR
Quantitative real time PCR was used to further validate the microarray
results. For these studies, RNA was extracted from control and IFN-γ
treated cell using TRIzol reagent Invitrogen (Carlsbad, California) and
residual DNA removed using the RNeasy Mini kit Qiagen (Valencia, CA).
Purified RNAs (2 μg) were then used as template for cDNA synthesis using
TaqMan Reverse Transcriptase Kit ABI Biosystems (Foster City, CA). Forty
nanogram aliquots of each cDNA were used for Real-Time PCR to
determine the expression levels of 18S rRNA, HLA-G, SOCS1, SOC3, and
CASP4 using primers and conditions described previously [33–36]. All
samples were run in triplicate and the experiment was repeated three times
with independently isolated RNA. Gene expression levels were normalized
to 18S using the comparative Ct method (2−ΔΔCT) as previously described
[37].3. Results
3.1. IFN-γ increases caspase-8 protein expression in NB cells
without affecting CASP8 methylation
Since previous studies had focused on the effects of IFN-γ in
caspase-8 deficient NB cell lines, we sought to determine the
frequency of caspase-8 induction in a larger panel of cells and to
determine whether caspase-8 expression could also be enhanced
in cell lines that already expressed this protein. Caspase-8
expression was quantitated in 16 NB tumor cell lines by
immunoblot analysis (Fig. 1A). All 10 NB cell lines with
methylated CASP8 alleles and absent/low expression of
caspase-8 exhibited increased protein expression after γ-IFN
treatment. IFN-γ exposure also increased caspase-8 expression
in three of six cell lines which expressed caspase-8 prior to IFN
treatment (Fig. 1A and Table 1). In accordance with the results
from previous studies, IFN-γ treatment did not alter the status of
CASP8 methylation in any of these cell lines (Fig. 1B and
[20,25]).
Fig. 1. Caspase-8 expression is enhanced by IFN-γ treatment without altering CASP8methylation status. (A) Immunoblot analysis of caspase-8 expression in NB cell
lines before (−) and 16 h after (+) treatment with 100 ng/ml IFN-γ for 120 min. Each lane in the top two panels contains 50 μg of the indicated protein lysates, while
panel 3 contains 30 μg of protein lysates from the caspase-8 expressing cell lines. To permit better comparison 50 μg of protein from the indicated cell lines with and
without IFN-γ treatment were compared directly. (B) MS-PCR analysis of the indicated cells lines before and after treatment with IFN-γ. The primers used are
indicated above each lane: the methylated primer set (M) produced a 321-bp product, and the unmethylated primer set (U) produced a 322-bp product. IFN-γ did not
alter the methylation status of the CASP8 alleles in any of the six representative NB cell lines.
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IFN-γ-induced caspase-8 expression
To determine the duration of IFN-γ exposure necessary to
induce caspase-8 protein expression, we exposed the cell lines
to 100 ng/ml IFN-γ for various lengths of time ranging from 5min to 48 h, washed the cells extensively with complete media
and incubated in standard media for the remainder of the
experiment. The IFN-γ treated cells were harvested 48 h after
the onset of treatment and the protein lysates were examined for
caspase-8 expression by immunoblot. This analysis revealed
that a 5 min exposure to 100 ng/ml IFN-γ was sufficient to
Table 1
Characteristics of 16 human neuroblastoma (NB) cell lines that expressed normal CASP8 alleles
Cell
Line
TNFR2 a
1p36−/−
MYCN
amplification b
Caspase-8
Expression
CASP8
Methylation
IFN-γ dose/Caspase-8
expression c
Relative increase in
Caspase-8 expression d
NB4 LOH >20 − + 2/100 3
NB5 LOH 2–5 + − 0 3
NB6 LOH >20 − + 0.5/20 3
NB8 LOH >20 − + 0.5/5 3
NB10 LOH >20 − + 0.5/0.5 4
NB13 LOH >20 − + 0.5/5 1
NB14 LOH >20 − + 10/20 2
NB15 WT >20 + − 0 2
NB16 LOH 2–4 + − 0.5/0.5 3
NB19 LOH >20 − + 10/10 3
NB1643 LOH 2–4 + − 0.5/0.5 3
NB1691 LOH >20 − + 0.5/2 2
NBEB LOH >20 − + 0.5/2 1
NBSB LOH >20 − + 0.5/2 1
SKNAS WT 2–4 + − 0.5/0.5 4
SKNSH LOH 2–4 + − 0 4
a Fluorescent in situ hybridization (FISH) using a probe for TNFR2 (tumor necrosis factor receptor 2) was used to determine whether1p36 was wild type (WT) or
showed a loss of heterozygosity (LOH).
b MYCN copy number as determined by FISH.
c The minimum IFN-γ concentration (ng/ml) capable of inducing Caspase 8 expression/ IFN-γ concentration resulting in maximal caspase-8 expression.
d The relative level of caspase-8 protein after IFN-γ treatment on a scale of 0 (lowest) to 4 (highest).
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IFN-γ exposure beyond 30 min did not further enhance
caspase-8 protein expression (Fig. 2A) and data not shown.
To determine the kinetics IFN-γ induction of caspase-8
protein and mRNA expression we measured caspase-8 mRNA
and protein in cells harvested at varying times intervals after
IFN-γ a two h IFN-γ treatment. RNase protection analysis
revealed that caspase-8 mRNA expression began to increase
approximately 10 h after IFN-γ treatment and reached a
maximal level at 12 h (data not shown). These data are
consistent with results from immunoblot studies that revealed
the maximal level of caspase-8 protein expression was achieved
16 h after exposure to IFN-γ (Fig 2B).
To determine the duration of IFN-γ-mediated effects on
caspase-8 expression, all 14 IFN-γ responsive neuroblastoma
cell lines were treated with 50 to 100 ng/ml of IFN-γ for 120
min. The cells were then collected 1-9 days after the removal of
IFN-γ for preparation of cellular lysates and immunoblot
analysis. The results demonstrated that caspase-8 was up-
regulated 1 day after treatment and remained elevated for 4 to 6
days (Fig. 2C). The level of caspase-8 returned to baseline 7–9
days post IFN-γ exposure (Fig 2C and data not shown). Finally,
repeated IFN-γ treatment (100 ng/ml exposure for 2 h followed
by a 16 h incubation period) demonstrated re-induction of
caspase-8 protein expression at levels similar to those observed
after the initial γ-IFN exposure (Fig. 2D).
3.3. Determination of IFN-γ dose required for caspase-8
induction
To define the dose of IFN-γ exposure necessary for caspase-
8 protein induction, NB cells were treated with various doses
IFN-γ (0.5–100 ng/ml) for 120 min followed by a 16 h cultureperiod. Five of 10 cell lines showed increased caspase-8
expression after a low dose of IFN-γ (0.5 ng/ml), and all ten
demonstrated substantial induction after treatment with 10 ng/ml
IFN-γ (Fig. 2E). Interestingly, although both the minimal and
maximal doses for caspase-8 induction varied for the different
cell lines, induction of caspase-8 protein expression was initially
IFN-γ concentration dependent but then reached a plateau and
could not be enhanced further in any of the cell lines by
increasing either the IFN-γ dose or the duration of treatment (see
Table 1, column 6). The degree of caspase-8 protein induction
varied across the cell lines tested, though overall maximum level
of expression after IFN-γ treatment was considerably lower in
the NB cell lines with low/absent caspase-8 genes than it was in
untreated caspase-8 expressing NB cell lines (Fig. 1A, bottom
panel). Preliminary experiments suggest it may be possible to
further increase the level of caspase-8 expression in at least a
subset of NB cells by sequential or combined treatment with
demethylating agents such as 5-aza-2′deoxycytidine and IFN-γ
(Fig. 2F). Similar data has also been obtained by other
investigators [38].
3.4. IFN-γ-mediated restoration of sensitivity to apoptotic
stimuli
To assess the functional integrity of the IFN-γ-induced
caspase-8 protein and determine whether the level of protein
expressed after IFN-γ treatment was sufficient for caspase-8-
dependent apoptosis, we examined the effects of prior IFN-γ
exposure on doxorubicin induced apoptosis. Although our
studies demonstrate maximal up-regulation of caspase-8
expression with IFN-γ exposure of 20 ng/ml or less, an IFN-γ
concentration of 100 ng/ml was chosen for the functional
apoptosis studies to facilitate comparison with data reported in
Fig. 2. Kinetics and time course of IFN-γ-induction caspase-8 in NB cells. (A) Immunoblot analysis of caspase-8 expression in NB8 and NB10 cell line. Cells were
treated with 100 ng/ml IFN-γ for 0 to 180 min, and lysates were prepared 16 h later. (B) Maximal caspase-8 protein levels were observed in all NB cell lines within 16 h
of IFN-γ treatment (100 ng/ml for 120 min). Results from 2 representative NB cell lines are shown. (C) Caspase-8 protein expression induced by IFN-γ (100 ng/ml for
120 min) persisted for 4 to 6 days. (+) indicates IFN-γ treated cells whereas (−) indicates untreated cells. (D) Repeated exposure (every 7 days) to 100 ng/ml of IFN-γ
for 120 min did not alter the level of caspase-8 protein expression. Cells were harvested 16 h after the first and third IFN-γ exposure and blotted for caspase-8 and actin
expression. (E) Analysis of IFN-γ concentration (ng/ml) required for induction of caspase-8 protein. Cells were treated for 120 min with the indicated concentration of
INF-γ, wash and harvested 16 h later for immunoblot analysis. Data for the other cell lines are summarized in Table 1. (F) Effects of sequential treatment of NB cells
with 5-aza-2′-deoxycytidine (1 or 5 μM as indicated) and IFN-γ (100 ng/ml) on NB14 and NB19. Enhanced caspase-8 expression was observed upon combination
treatment for NB19 but not in NB14.
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doxorubicin, IFN-γ, and z-IETD-fmk on apoptosis in 4 NB cell
lines with MYCN amplification and low/absent caspase-8
protein expression under a variety of experimental conditions
by TUNEL. IFN-γ induction of caspase-8 expression altered the
sensitivity of these cells to doxorubicin, a chemotherapeutic
drug that has been reported to initiate apoptosis predominantly
through the extrinsic (i.e., Fas/CD95) arm of the apoptotic
pathway in NB tumor cells [14]. Similar data were obtained
upon treatment of the cell lines used in Fig. 3 with the IFN-γ
dosage required for maximal caspase-8 protein production (data
not shown).
The median basal level of apoptosis in untreated cells was
9.6% (range 1.1%–14.4%) (Fig. 3). No significant increase in
the percentage of apoptotic cells was observed after treatment
with either IFN-γ alone (median level of apoptosis 11.4%;
range 8.9%–16.3%) or z-IETD-fmk alone (median 10.8%;
range, 7%–21.1%). However, a dramatic increase in the level of
apoptosis was observed in cells treated with both IFN-γ and
doxorubicin (median 59%; range 40.5%–81.9%). Furthermore,
this level of cell death was significantly greater than the sum of
the percentages of apoptotic cells seen in cultures treated with
either IFN-γ or doxorubicin alone, indicating that the sequential
administration of IFN-γ and doxorubicin resulted in an
amplified apoptotic response. The addition of z-IETD-fmk to
cell cultures treated with IFN-γ and doxorubicin resulted in a
substantial but not complete decrease in the apoptotic responses
(Fig. 3). This result supports the involvement of caspase-8 in
doxorubicin-induced cell death in NB cells. However, since
z-IETD does not completely eliminate doxorubicin induced
apoptosis, other caspases and/or proapoptotic proteins may
also be induced by exposure to IFN-γ thereby increasing the
apoptotic response of NB cells to treatment with chemother-
apeutic agents. Indeed, the microarray data support this
hypothesis.Fig. 3. Comparison of apoptosis in 5 NB cell lines. Apoptosis levels of NB cells
TUNEL assay. Single-agent treatments included doxorubicin (dox; 0.1 μg/ml), IF
consisted of IFN-γ (100 ng/ml) followed by doxorubicin (0.1 μg/ml) alone or dox
error of the mean from duplicate slides from 3 independent experiments.3.5. IFN-γ-induced alterations in the expression of many genes
that have potential roles in neuroblastoma tumorigenesis
To assess the effects of IFN-γ on global gene expression we
used microarray analysis to compare mRNA expression in 4 NB
cell lines (NB10, NB16, NB19, and NB1643) before and after
IFN-γ exposure. NB10 and NB19 cells contained amplified
MYCN alleles and, before IFN-γ treatment, exhibited very low
caspase-8 expression. In contrast, NB16 and NB1643 cells
expressed caspase-8, and their MYCN loci were not amplified.
Alterations in RNA expression were validated by real time
quantitative PCR using primers specific for HLA-G, SOCS1,
SOCS3 and caspase 4. Data from this quantitative PCR analysis
were similar to the microarray data in all cases. For example,
microarray analysis ofmRNA isolated from untreated and IFN-γ
treated NB10 cells yielded an average increase in SOCS1 and
caspase-4 expression of 13.4- and 3.2-fold respectively in the
IFN-γ treated cells while real time PCR indicated a 12.1-fold in
SOC1 expression and a 3.1-fold increase in caspase-4 expres-
sion. Similar data were obtained for the other cell lines with all
four sets of primers (data not shown).
The microarray revealed substantial variation in gene
expression levels between the cell lines, although the data
from the three independent experiments were very similar for
each cell line. However, the majority of the genes exhibiting
significant changes in expression could be grouped into 5
somewhat overlapping functional pathways using the Ingenuity
Pathways Analysis Solution and Knowledge Base software
program. The first functional group contained sixty-five
apoptosis-related genes which showed 2-fold or greater change
in mRNA levels after treatment with IFN-γ (P≤0.05) in one or
more cell lines in each of three independent experiments.
Although there was inter-cell line variability in the IFN-γ
mediated induction of some apoptotic genes, we were able to
identify a set of genes whose expression is likely to be altered inwhich increase caspase-8 expression after IFN-γ treatment were assessed via
N-γ (100 ng/ml) and z-IETD-fmk (z-IETD; 50 μM). Multi-agent treatments
orubicin (0.1 μg/ml) plus z-IETD-fmk (50 μM). Error bars represent standard
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tion or CASP8 intron3/exon3 methylation status (Table 2). For
example, three of the 4 cell lines showed increased CASP4,
CASP5, CASP7, and BCL-6 mRNA expression, and 2 of the
4 showed increased CASP1 and CARD4 (Table 2). Interestingly,
CASP8 mRNA expression was significantly increased in only
the NB16 cell line using the criteria described above, although
RNAse protection assays revealed increased RNA expression in
all four cell lines and immunoblots showed a greater than 2-fold
increase in caspase-8 protein expression in all 4 cell lines (Fig. 1
and data not shown). The expression of 58 genes associated
with cell cycle regulation and 50 genes with roles in
transcription or signal transduction was also altered in the
various cell lines. Again, a small subset of genes involved in cell
cycle (i.e., CDKN1A, SOCS1, SSTR2 and TYM) and growth
inhibition and differentiation (i.e., IRF-1, SOCS3, and STAT-1)
showed increased expression, while those that promote cell
division (i.e., ARG2, RGS2, and SOCS2) showed reduced
expression in two or more cell lines (Table 2). Finally, we
identified fifty immune response genes whose expression was
effected by IFN-γ exposure in the various cell lines. A set of
common genes with enhanced expression and functional role in
promoting cellular differentiation and immune cell function
(i.e., CXCL11, HLA-B, and IL12A) was observed this group.Table 2
Microarray mRNA expression analysis
Function NB16 NB1643 NB10 NB19
Apoptosis
CASP4↑, CASP5↑, PLP1↑ X X X
IRS1↑ X X X
CASP7↑, BCL6↑ X X X
TNFRSF1B↑ X X
CASP1↑, CARD4↑ X X
EVI1↓, IGFSBP4↑ X X
CASP8↑, X
Cell cycle/proliferation
SOCS1↑ X X X X
CDKN1A↑ X X X
SSTR2↑ X X
TYMS↓ X X
Signal transduction/transcription factors
SOCS3↑ X X X X
HLA-B↑, IRF1↑ X X X
CXCL10↑ X X X
STAT1↑ X X
RGS2↓, SOCS2↓ X
IRF7↑ X X
ARG2↓ X X
Immune response
HLA-G↑, LGALS3BP↑ X X X X
CX3CL1↑, G1P2↑, HLA-B↑ X X X
B2M↑ X X X
CXCL11↑ X X
IL12A↑ X X
TRIM22↑ X X
X, gene is expressed.
↑, expression is increased≥2-fold, p>0.05.
↓, expression is decreased≤2-fold, p>0.05.4. Discussion
Neuroblastoma is the most common pediatric solid tumor that
does not involve the central nervous system (CNS), constituting
20% of all pediatric non-CNS solid tumors in children aged 0 to
14 years [39,40]. At diagnosis, 80% of patients have advanced-
stage (stages III or IV) or high-risk disease (e.g., MYCN
amplified, chromosome 1p36.3 deletion, unfavorable histol-
ogy). Historically, survival of these patients is less than 15%
[39,40]. Although the implementation of high-dose myeloabla-
tive therapy with hematopoietic stem cell reconstitution has
improved remission rates and prolonged event-free survival,
long-term survival in patients with advanced-stage or high-risk
neuroblastoma remains poor [41]. Relapsed disease in these
patients is usually resistant to therapy [42]. Caspase-8 is not
expressed in approximately 70% of NB cell lines and tumors
with MYCN amplification and 1p36.3 LOH [13]. Absence of
caspase-8 is also associated with resistance to cytotoxic drugs
[13]. Lack of caspase-8 protein expression has been correlated
with resistance to conventional chemotherapy in neuroblastoma
and medulloblastoma in vitro and with clinical prognosis in
medulloblastoma patients [8,15]. Recently, other investigators
have shown that caspase-8 expression is induced in NB cells
after prolonged IFN-γ exposure [20–25], a finding with
potential clinical significance.
IFN-γ is a member of the IFN family of multifunctional
cytokines with immune modulatory, antiproliferative, differ-
entiation-promoting, and proapoptotic effects [26–28]. More
than 200 genes are reported to be regulated by IFN-γ, and most,
if not all, IFN-γ-dependent effects are mediated through IFN-
receptors and the JAK/STAT (Janus kinase/signal transducers
and activators of transcription) pathway [26,27,43–46]. The
changes in expression a heterogeneous group of cytostatic and
apoptotic genes, in response to IFN-γ treatment appears to be
determined by cellular context and prevailing microenviron-
ment [26–28].
Although the mechanism is not completely understood, IFN-
γ-mediated up-regulation of caspase-8 expression occurs
through the JAK/STAT1 signal transduction pathway
[20,25,46]. A key regulatory transcription factor in this process
is interferon regulatory factor-1 (IRF-1) [20,25–28,43–46]. IRF-
1 is a proapoptotic transcription factor induced by STAT1 that
enhances STAT1-mediated transcriptional activation of caspase-
8 [20,25,46]. Multiple caspase-8 isoforms have been identified,
the majority of which function as proapoptotic mediators.
Analyses of the human CASP8 sequence have identified
STAT1 and IRF-1 binding sites in the promoter region of the
caspase-8 gene [24,25,46,47,49] within a hyper-methylated
region of the exon3/intron3-boundary and throughout the
caspase-8 genomic sequence. IFN-γ stimulation of NB cells
withCASP8methylation and low caspase-8 protein levels results
in expression of two of the known proapoptotic caspase-8
isoforms, caspase-8a and caspase-8b, without altering intergenic
methylation (Fig. 1 and [20,22,25]). Therefore, it remains unclear
whether these sites and/or other interferon-sensitive response
element sequences localized to other regions of the gene play any
role in chromatin structure and/or caspase-8 expression.
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in the treatment of cancer, including neuroblastoma; however, these
studies were performed under a single (or at most a few)
experimental condition(s) [20–24,46]. Here we determined the
dosage and kinetic properties of IFN-γ treatment and verified that
the resulting induction of caspase-8 dramatically resensitized NB
cells to chemotherapeutic drug-induced apoptosis. Our data
indicate exposure to IFN-γ for 5 min is sufficient to induce
caspase-8 expression in all of the NB cell lines with absent or low
caspase-8 expression and to enhance caspase-8 expression in half
(3/6) of cell lines that already expressed caspase-8. Moreover,
increased caspase-8 mRNA expression was not detected until 12 h
after IFN-γ exposure and maximal protein production was not
observed until 16 h after stimulation suggesting that IFN-γ signals
caspase-8 mRNA transcription and translation. Although low level
caspase-8 expressionwas observed at INF-γ concentrations of 0.5–
10 ng/ml, raising the dose of IFN-γ to 20–50 ng/ml resulted in
maximal levels of caspase-8 protein. Caspase-8 expression then
reached a plateau; no further increases in caspase-8 expressionwere
observed beyond 20–50 ng/ml IFN-γ or with exposures beyond 30
min. Caspase-8 protein expression was maximally induced 16 h
after treatment and was maintained for 4 to 6 days before gradually
declining and ultimately disappearing approximately 5–9 days
after treatment.
Although IFN-γ enhanced caspase-8 protein expression,
microarray analysis demonstrated significant (>2-fold) up-regula-
tion of CASP8 in only 1 of the 4 cell lines at the transcriptional
level. RNAse protection analysis revealed small, but significant,
increases in caspase-8 transcripts in IFN-γ responsive cell lines.
The likely explanation for these discrepant findings is the relative
sensitivities of these two techniques and the 2-fold threshold used
to identify significant differences by microarray [50]. Additionally,
the relatively small increase in caspase-8 mRNA expression
suggests that IFN-γ may also enhance caspase-8 protein
expression at the post-transcriptional level.
The functional consequences of the IFN-γ effects in NB cells
are dramatic and demonstrate that an amplified apoptotic
response to doxorubicin in vitro can be obtained when IFN-γ
and doxorubicin are administered sequentially. Similar results
have been obtained by IFN-γ treatment of human myeloid
leukemia, breast cancer and Ewing's sarcoma cells [48,51,52].
Our studies suggest that this apoptotic response is, at least in
part, a consequence of caspase-8 activity because treatment of
caspase-8-positive NB cell lines with z-IETD-fmk, a relatively
specific caspase-8 inhibitor, decreased their sensitivity to
doxorubicin-induced apoptosis. These observations support
the assertion that in neuroblastoma, caspase-8 plays an
important role in development of tumor cell resistance to
some chemotherapeutic agents. However, the microarray
analysis of IFN-γ-treated NB cell lines revealed up-regulation
of transcripts for several other caspases and proapoptotic
proteins, and down-regulation of several antiapoptotic and pro-
proliferative transcripts. Indeed, increased expression of
caspases-4, -5, and -7 might explain the observation that a
small portion of the apoptotic activity we observed was not
inactivated by treatment with z-IETD. This finding suggests that
IFN-γ may also affect the responses of NB cells tochemotherapeutic agents that work via the mitochondrial
(intrinsic) pathway.
The theoretical extrapolation of these data to in vivo systems
suggests that physiologically achievable exposure times and
systemic concentrations of IFN-γ are possible for treatment of
patients with advanced-stage neuroblastoma. Information
regarding IFN-γ therapy for pediatric malignancies is extremely
limited; only 2 phase I clinical studies using IFN-γ alone have
been reported to date [53,57]. In both studies, IFN-γ
monotherapy was used as an immune modulator and was
intended to augment or facilitate the host's antitumor response.
Results from those studies were encouraging, but further studies
have not yet been reported. Though extensive pharmacokinetic
data are lacking, serum IFN-γ concentrations of 1.6–2.4 ng/ml
were seen in patients receiving 325 μg/m2 of IFN-γ [54].
Another study described successful administration of IFN-γ at
doses of 0.8–2.7 μg/m2 yielding serum IFN-γ concentrations of
5–20 ng/ml [55]. Of note, induction of caspase-8 was observed
in IFN-γ responsive cell lines upon exposure to IFN-γ
concentrations of 10 ng/ml or less, suggesting it should be
possible to up-regulate caspase-8 expression in vivo [55–57].
Indeed, Thiele and coworkers [22] recently re-evaluated
archived NB specimens obtained before and after IFN-γ
treatment for caspase-8 expression and observed induction of
caspase-8 after IFN-γ treatment in several of the biopsied
tumors. This finding supports the conclusion that IFN-γ can
induce caspase-8 expression in vivo.
Clinical trials of IFN-γ combined with conventional
chemotherapeutic agents to treat adult patients with melanoma,
ovarian, colon, or renal cell carcinoma have yielded promising
results [58–65]. Based on our studies and the in vitro work from
other laboratories and the analysis of archived biopsy samples
from a previous small scale single agent IFN-γ clinical trial in
human NB patients, we propose that IFN-γ be administered
before cytotoxic therapy, not as an immunemodulating agent but
as a chemosensitizer to render tumors more responsive to
conventional chemotherapy. As such, the temporal relationship
and timing of IFN-γ and cytotoxic agent administration is
important. IFN-γ treatment should precede that of conventional
chemotherapeutic agents, allowing enough time for up-regula-
tion of caspase-8 expression. Following IFN-γ exposure, the
consequent enhanced caspase-8 expression appears to persist for
several days. Our studies demonstrated enhanced cytotoxicity
with doxorubicin treatment during this window post IFN-γ
exposure in vitro. This sustained response should allow
chemotherapy to be administered either by protracted contin-
uous infusion or on a repetitive dosing schedule. Variations on
this scheme have been proposed recently by other investigators
based on their cell culture studies [22,66]. In these studies, these
investigators evaluated the apoptotic sensitivity to TRAIL (i.e.,
TNF receptor apoptosis-inducing ligand) in tumor cells
pretreated with chemotherapeutics (to enhance TRAIL2 receptor
expression) and IFN-γ (to induce caspase-8 expression). These
treatments induced caspase-8 protein expression in tumor cell
lines and renewed their sensitivity to TRAIL-mediated apoptosis
[22,66]. These results are similar to those of Debatin and
coworkers [20,21] who demonstrated that IFN-γ exposure
1009T.M. Tekautz et al. / Biochimica et Biophysica Acta 1763 (2006) 1000–1010increased Fas/CD95 expression and sensitized NB tumor cells to
apoptosis, an effect that was further enhanced in the presence of
MYCN amplification [20,21]. We conclude that additional
investigation is warranted to evaluate the clinical utility of
sequential administration of IFN-γ, doxorubicin and potentially
even 5-aza-2′-deoxycytidine or other chemotherapeutic drugs to
treat pediatric patients with refractory, late-stage neuroblastoma.
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